Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals
This article was originally published in The Pink Sheet Daily
Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.
You may also be interested in...
Anthera's planned offering will be the first real IPO in 18 months and a good indicator of whether there are signs of life in the biotech IPO market.
Adimab CEO Gerngross wouldn't disclose the amount of Series D money raised, but promised "there will be interactions" between Adimab and parent company Google.
Members agree 12-0 that drug is approvable, offer opinion on who should dispense and the amount of training needed.